Managers / Q1 2025 · view latest →
Almitas Capital LLC
CIK 0001596468 · 1335 4TH STREET, SUITE 400, SANTA MONICA, CA, 90401 · 310-573-4343
Summary
Almitas Capital LLC reported $301M in U.S.-listed holdings across 81 positions for Q1 2025.
The portfolio is heavily concentrated: FBTC alone accounts for 39.5% of reported value.
Compared with Q4 2024, the fund opened 14 new positions and exited 25.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Closed-End Fund · 41.6% · $125M
- ETP · 40.1% · $121M
- Common Stock · 11.6% · $35M
- Other · 3.6% · $11M
- REIT · 2.1% · $6M
- Other · 0.9% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CNNECannae Holdings Inc | NEW | +143.7K | 143.7K | +$3M | $3M |
| MSGSMadison Square Garden Sports Corp | NEW | +9.9K | 9.9K | +$2M | $2M |
| PIMCO California Municipal Income Fund | NEW | +204.5K | 204.5K | +$2M | $2M |
| Wheeler REIT INC | NEW | +5.3K | 5.3K | +$966,491 | $966,491 |
| CIMChimera Investment Corp | NEW | +66.8K | 66.8K | +$857,544 | $857,544 |
| CABACabaletta Bio Inc | NEW | +367.5K | 367.5K | +$508,975 | $508,975 |
| CCAPCrescent Capital BDC Inc | NEW | +24.2K | 24.2K | +$414,304 | $414,304 |
| XJEQXabrdn Japan Equity Fund Inc | NEW | +60.6K | 60.6K | +$394,035 | $394,035 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $443M | 115 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $454M | 107 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025REVEALED | $867M | 128 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $396M | 82 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $301M | 81 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $456M | 92 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $283M | 69 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $241M | 76 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $242M | 69 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $290M | 116 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $209M | 88 | Nov 21, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2023 | $234M | 92 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $209M | 97 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $217M | 128 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $134M | 87 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $193M | 119 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $168M | 85 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $99M | 54 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 46 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $80M | 46 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $45M | 46 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $115M | 65 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $93M | 47 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $96M | 55 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $140M | 60 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $148M | 85 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.